Deadline October, 6th 2019
BRIO is looking for outstanding scientists to complement the cancer research community in Bordeaux, France.
SIRICs (Integrated Cancer Research Sites) were initiated by the 2nd French Cancer Plan to optimise and accelerate the production of new knowledge, promote its dissemination and application in cancer management. BRIO (Bordeaux Integrated Research in Oncology) is one of eight French sites to be given SIRIC status by the INCa (French National Cancer Institute) for 2018-2022. This renewal of BRIO’s SIRIC status is a tribute to the excellence delivered by BRIO during 2013-2017 and to the relevance of its new programme. Through BRIO, multidisciplinary research teams work in synergy in Bordeaux to produce new knowledge in oncology and accelerate its transfer for the benefit of patients within three innovative integrated research programmes: PrIME: Programme for Improved Management of Elders with Cancer; IMS: Integrated Medicine for Sarcomas; COMMUCAN: Intercellular COMMUnication in CANcer biology and Therapy. BRIO involves scientists and physicians that contribute, in and beyond biology, to the fight against cancer, in such diverse fields as: humanities and social sciences, public health, epidemiology, clinical, physical sciences, chemistry, mathematics, computer science… An ambitious approach to improve the link between patients and research is also an important part of BRIO’s overall strategy.
BRIO’s trustees are Bordeaux University, the comprehensive cancer centre – Institut Bergonié, Bordeaux University Hospital, Inserm (the national institute for biomedical research and human health) and CNRS (National Center for Scientific Research). These institutions work efficiently together and can rely on significant annotated tumour banks and databases, in particular in geriatric oncology, sarcomas, kidney, breast, gliobastoma and liver.
Bordeaux cancer research is presently benefiting from major investments from the Nouvelle-Aquitaine regional council as well as strong involvement from Bordeaux University, Inserm and CNRS institutions. This will foster a rich structured and unique transdisciplinary research environment, which aims to accelerate multidisciplinary collaboration (including with patients) and production, over the next few years.